July 24, 2020

Akebia Therapeutics has announced a voluntary recall of 13 lots of Auryxia® (ferric citrate) 210mg tablets for wholesalers and retailers. The lots in question were not manufactured in conformance with the FDA-approved manufacturing process. Auryxia is indicated to treat iron deficiency anemia in adults who have chronic kidney disease and are not on dialysis.

As of the date of the recall, no adverse events related to the affected lots had been reported. Akebia stated there are no known health risks associated with the recalled product. Wholesalers and retailers have been notified and asked to discontinue distribution of Auryxia belonging to the affected lots, and to return unopened product.

The recall does not extend to the member level.

July 24, 2020

Tecartus Approved as First CAR-T Therapy for Mantle Cell Lymphoma

Read More
July 24, 2020

Select Lots of Auryxia Recalled

Read More
July 23, 2020

FDA Recommends Healthcare Professionals Discuss Naloxone with Patients when Prescribing Opioids

Read More
July 22, 2020

Wynzora Cream Approved for Plaque Psoriasis

Read More